Oncolytics Biotech (ONCY) Total Current Liabilities (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Total Current Liabilities data on file, last reported at $6.1 million in Q4 2025.

• On a quarterly basis, Total Current Liabilities rose 27.45% year-over-year to $6.1 million in Q4 2025; TTM through Dec 2025 was $6.1 million, a 27.45% increase from a year earlier, with the FY2025 full-year figure at $6.1 million, up 24.89% from the prior year.
• Total Current Liabilities for Q4 2025 stood at $6.1 million, up from $5.6 million in the prior quarter.
• Over the last five years, Total Current Liabilities for ONCY reached as high as $7.5 million in Q3 2023 and fell as low as $1.8 million in Q1 2023.
• Historically, Total Current Liabilities has averaged $3.5 million across 5 years, with a median of $3.0 million in 2022.
• Across the five-year window, Total Current Liabilities sank 55.71% in 2021 and soared 165.84% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $2.1 million in 2021, then soared by 36.19% to $2.9 million in 2022, then advanced by 7.09% to $3.1 million in 2023, then soared by 53.81% to $4.8 million in 2024, then grew by 27.45% to $6.1 million in 2025.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $6.1 million in Q4 2025, $5.6 million in Q3 2025, and $4.7 million in Q2 2025.